Shiv Texchem Ltd H1 FY26 – ₹1,503 Cr Sales, ₹43 Cr PAT, 5x P/E, and a Sanctions Plot Twist Nobody Asked For
1. At a Glance – Chemical King or Imported Chaos?
Shiv Texchem Ltd is that guy in the chemical market who doesn’t manufacture anything, yet somehow manages to clock ₹1,503 crore in half-year sales and ₹43 crore in net profit, while the stock quietly bleeds 44% in three months and 58% in one year like it’s auditioning for a tragic Bollywood role. Market cap sits at around ₹360 crore, CMP at ₹155, and the stock trades at a scandalously low P/E of ~5.1, in an industry where peers flex triple-digit valuations like Instagram influencers flex abs. ROE is a respectable 18.3%, ROCE at 14.5%, but debt is chunky at ₹431 crore, giving it a debt-to-equity of 1.15. The latest half-year results (H1 FY26, locked and loaded) show revenue momentum, margin expansion, and profit growth north of 100% YoY, yet the stock price behaves like it just read its own news section and panicked. Add an IPO just a year ago, sanctions drama, paused USD credit lines, and a chemical trading business running on thin margins, and you’ve got a spicy cocktail. Curious already? Good. You should be.
2. Introduction – Welcome to the Import-Export Olympics
Shiv Texchem was incorporated in 2005, long before SME IPOs became the new Zomato delivery trend. For nearly two decades, it has done one thing consistently: import hydrocarbon-based chemicals and distribute them across India. No factories, no reactors, no smoke-belching chimneys—just sourcing, storing, and supplying chemicals to anyone who needs them, from paint makers to pharma giants.
On paper, this sounds boring. In reality, it’s a high-volume, low-margin knife fight where scale is king, working capital is the real boss, and one delayed shipment can ruin your quarter. Shiv Texchem plays this game with 39 products, 60+ suppliers, and 650+ customers, including names like Pidilite, Berger, Reliance Industries, Vinati Organics, Glenmark Life Sciences, and others who don’t usually buy chemicals from amateurs.
The company went public in October 2024, raising ₹105 crore, and immediately discovered that public markets are less forgiving than private negotiations. Despite strong financial growth, the stock has been hammered. Why? Thin margins, rising debt, working capital stress, and then—just to spice things up—its name appearing on the US Treasury OFAC sanctions list in October 2025, triggering paused USD credit lines.
So the big question: is Shiv Texchem a misunderstood cash machine trading at absurd valuations, or a working-capital-heavy trader one headline away from chaos? Let’s dissect this molecule by molecule.
3. Business Model – WTF Do They Even Do?
Shiv Texchem is essentially a chemical supermarket with a global sourcing engine. It doesn’t manufacture acetone or styrene monomer; it imports them from global and domestic suppliers, stores them at ports and contracted facilities, and sells them to Indian customers who don’t want the headache of import logistics.
Its product list reads like a chemistry exam paper: Acetyls, alcohols, aromatics, solvents, inorganics, phenolics, ketones, glycols, monomers, intermediates—you name it, they’ll source it. From acetic acid to styrene monomer, from caustic soda to aniline, Shiv Texchem is the middleman your factory depends on but never invites to the annual day.
The real value-add is not the product; it’s the aggregation and negotiation. Shiv Texchem pools demand from multiple customers, negotiates prices and specs with suppliers, arranges storage at ports like Kandla, Mundra, JNPT, Hazira, and handles logistics. For sensitive chemicals, it even offers specialized storage. Basically, it’s logistics + finance + relationships.
But here’s the catch: top 5 products contribute ~48% of revenue, top 10 ~74%. That’s concentration risk wearing a lab coat. One product cycle goes wrong, margins sneeze, and profits catch a cold. Is scale enough to offset this? Or is the business permanently living on 4–5% operating margins? Think about it.
4. Financials Overview – Numbers Don’t Lie, They Just Smirk
Result Type Lock: HALF-YEARLY RESULTS (H1 FY26)
Annualised EPS = Latest EPS × 2
Financial Comparison Table (₹ Crore)
Source table
Metric
Latest H1 (Sep 2025)
YoY H1 (Sep 2024)
Prev Half (Mar 2025)
YoY %
HoH %
Revenue
1,503
1,031
1,171
45.8%
28.4%
EBITDA
73
35
51
108.6%
43.1%
PAT
43
21
27
104.8%
59.3%
EPS (₹)
18.54
12.09
11.86
53.4%
56.3%
Annualised EPS (H1 FY26) = 18.54 × 2 = ₹37.08
At a CMP of ₹155, that’s an implied P/E of ~4.2, even cheaper than the reported trailing P/E. Either the market thinks this profit is a one-time fluke, or it’s pricing in future headaches. Revenue growth is strong, EBITDA margins expanded to ~5%, and PAT doubled YoY. On pure numbers, this looks delicious. So why is the stock sulking? Hold that thought.
5. Valuation Discussion – Cheap for a Reason or Reasonably Cheap?
Method 1: P/E Based Valuation
Annualised EPS: ₹37.08
Conservative P/E band (chemical traders): 6x – 10x
Fair Value Range (P/E): ₹220 – ₹370
Method 2: EV/EBITDA
TTM EBITDA: ~₹124 crore
EV: ~₹541 crore
EV/EBITDA: ~4.2x
Peer trading range: 6x – 10x
Implied EV Range: ₹744 – ₹1,240 crore After adjusting
